Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
| Autor: | Rajesh K. Malik, Yili Pritchett, Jennifer Johnson, Balazs Medgyasszay, Shannon R. Morris, Renata Ferrarotto, Trevor M. Feinstein, William Jeffery Edenfield, Maria Rosario García-Campelo, Ian Anderson, Tibor Csőszi, Alfredo Sanchez-Hernandez, Sujith Kalmadi, Philip E. Lammers |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Lung Neoplasms Neutropenia Anemia medicine.drug_class medicine.medical_treatment Phases of clinical research Antineoplastic Agents Placebo granulocyte colony‐stimulating factor Double-Blind Method Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Pyrroles red blood cell transfusion RC254-282 Research Articles Randomized Controlled Trials as Topic Retrospective Studies Myelosuppressive Chemotherapy Chemotherapy trilaciclib business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens Clinical Cancer Research medicine.disease Erythropoiesis-stimulating agent anemia Small Cell Lung Carcinoma erythropoiesis‐stimulating agent Granulocyte colony-stimulating factor Pyrimidines Oncology Female business Research Article |
| Zdroj: | Cancer Medicine Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021) |
| ISSN: | 2045-7634 0249-9770 |
| Popis: | Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome to patients and associated with greater costs to health care systems. We evaluated the utilization of supportive care interventions and their relationship with the myeloprotective agent, trilaciclib. Methods Data were pooled from three independent randomized phase 2 clinical trials of trilaciclib or placebo administered prior to chemotherapy in patients with extensive‐stage small cell lung cancer (ES‐SCLC). The impact of supportive care on the duration of severe neutropenia (DSN), occurrence of severe neutropenia (SN), and occurrence of RBC transfusions on/after week 5 was analyzed across cycles 1–4. Concordance and association between grade 3/4 anemia, RBC transfusions on/after week 5, and ESA administration was also evaluated. Results The use of G‐CSFs, ESAs, or RBC transfusions on/after week 5 was significantly lower among patients receiving trilaciclib versus placebo (28.5% vs. 56.3%, p Compared with placebo, administering trilaciclib prior to chemotherapy reduces chemotherapy‐induced neutropenia and anemia, with a reduction in the use of hematopoietic growth factors and red blood cell transfusions. By improving key myelosuppressive endpoints and reducing the need for associated supportive care, trilaciclib has the potential to reduce both the societal and economic burden of chemotherapy‐induced myelosuppression on patients with extensive‐stage small cell lung cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|